You are here: Industry Insights > Amgen

News List

EVOQ Announces License, Collaboration Agreement with Amgen americanpharmaceuticalreview
January 21, 2021
EVOQ Therapeutics announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders.
EVOQ Therapeutics and Amgen Partner contractpharma
January 14, 2021
EVOQ Therapeutics has signed a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders.
Tezepelumab Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
January 08, 2021
Amgen and AstraZeneca announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with tezepelumab compared to placebo.
Amgen Submits Sotorasib Marketing Authorization Application to EMA americanpharmaceuticalreview
December 28, 2020
Amgen announced submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotorasib, an investigational KRASG12C inhibitor, for the treatment of adult patients with previously treated KRAS G12C-mutated ...
Amgen files KRAS inhibitor sotorasib with EMA pharmatimes
December 24, 2020
Amgen has submitted a marketing authorisation application the European Medicines Agency (EMA) for its investigational KRAS inhibitor sotorasib for previously-treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).
AZ, Amgen’s SOURCE trial misses primary endpoint pharmatimes
December 23, 2020
AstraZeneca and Amgen have announced that a phase III trial of their new medicine tezepelumab failed to meet the primary endpoint in patients with severe, oral corticosteroid-dependent asthma.
Amgen’s sotorasib gets FDA breakthrough therapy status to treat advanced KRAS G12C-mutant NSCLC pharmaceutical-business-review
December 10, 2020
Amgen has secured a breakthrough therapy designation from the US Food and Drug Administration (FDA) for its sotorasib to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation.
Amgen hands back heart failure programme rights to Cytokinetics pharmatimes
November 25, 2020
Amgen has handed back the rights to two investigational heart failure programmes to Cytokinetics after one of the drugs failed to demonstrate impressive results in a phase III study.
Amgen Ends Cardio Alliance with Cytokinetics contractpharma
November 24, 2020
Amgen has terminated its collaboration with Cytokinetics and intends to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594.
Tezepelumab Trial Meets Primary Endpoint americanpharmaceuticalreview
November 20, 2020
Amgen and AstraZeneca announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page